Powerful Intelligence for Dealmakers
The following sample deal entries offer an insight into the level of detail you can expect when subscribing to Current Agreements.
Lantheus Holdings and POINT Biopharma Global announced a set of strategic collaboration agreements in which Lantheus will license exclusive worldwide rights to POINT’s PNT2002 and PNT2003 product candidates more
Coya Therapeutics announced expansion of its exclusive worldwide rights for the development and commercialization of COYA 301, the Company’s low-dose IL-2 subcutaneous administration product candidate more
Phase Genomics and Element Biosciences released new details of their first collaboration leveraging Phase Genomics’ proprietary OncoTerra cytogenomics platform and the Element AVITI System for next generation sequencing more
Verge Genomics announced a three-year collaboration with Eli Lilly to research and develop novel therapies for the treatment of amyotrophic lateral sclerosis more
Astellas Pharma and Iveric bio announced the Companies have entered into a definitive agreement under which Astellas through Berry Merger Sub has agreed to acquire 100% of the outstanding shares of Iveric Bio in cash for a total equity value of approximately US$5.9 billion more
Pfizer will acquire Seagen, a global biotechnology company that discovers, develops and commercializes transformative cancer medicines, for $229 in cash per Seagen share for a total enterprise value of $43 billion more